GSK Jumps On Solid Earnings, Says It's 'Well Positioned' To Navigate TariffsInvestors Business Daily • 04/30/25
GSK: Disproportionately discounted, but earnings beat shows signs of reappraisalProactive Investors • 04/30/25
GSK update brings US vaccine exposure into spotlight, as sceptic RFK Jr loomsProactive Investors • 04/25/25
GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59Zacks Investment Research • 04/17/25
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's DiseaseGlobeNewsWire • 04/17/25
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization PracticesBusiness Wire • 04/16/25
GSK's 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization PracticesBusiness Wire • 04/16/25
GSK in breach for misleading prescribing information on Omjjara, industry body saysReuters • 04/15/25
AstraZeneca and GSK retain defensive qualities, but tariff assault on sector could change thatProactive Investors • 04/10/25
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkbackCNBC • 04/10/25
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play OutSeeking Alpha • 04/09/25